ProPhase Labs corrects Q1 EPS to $(0.35) from $(0.07); net loss $6.3M on revenue decline

ProPhase Labs, Inc.

2024-Q1 EPS reported -$0.35 revenue$3,634,000

Corrected diluted EPS $(0.35) vs originally $(0.07); weighted average shares corrected to 18.0M from 90.4M.
Q1 net loss of $6.3M vs net income of $0.6M a year ago; revenue fell 81% to $3.6M as COVID testing ended.
Pharmaloz exploring potential sale or long-term capacity agreements; line two expected $40-$45M revenue capacity in Q3.
BE-Smart esophageal cancer test on track for H2 2024 commercialization; launched AI initiative Project ZenQ-AI.
Cash at April 30 was $4.6M; raised $2.5M via receivable securitization and collected $3.6M from partial investment sale.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ProPhase Labs, Inc. reported financial results for the three months ended March 31, 2024.

Period: the three months ended March 31, 2024
Result: reported results

Exact text from the filing

ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

ProPhase Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-018499

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.